

The potential usefulness of sputum cytology in the conclusive diagnosis of methotrexate-associated lymphoproliferative disorders: A case report

Journal:	<i>SAGE Open Medical Case Reports</i>
Manuscript ID	SOMCR-IJSP-18-0516.R2
Manuscript Type:	Case Report
Date Submitted by the Author:	n/a
Complete List of Authors:	Mizuguchi, Seiya; Kanazawa Medical University, Department of Pathology Mizutani, Kenichi; Kanazawa Ika Daigaku, Yamashita, Manabu; Kanazawa Medical University, Department of Pathology Minato, Hiroshi; Ishikawa Prefectural Central Hospital, Department of Pathology Yamada, Sohsuke; Kanazawa Medical University, Pathology and Laboratory Medicine
Keywords:	Pathology
Additional Keywords:	Methotrexate-associated lymphoproliferative disorders (MTX-LPD), Sputum
Abstract:	<p>Methotrexate (MTX) has been used as an anchor drug for the treatment of rheumatoid arthritis (RA) and is considered to be a cause of MTX-associated lymphoproliferative disorder (MTX-LPD). Spontaneous regression can occur after withdrawal of MTX and may be associated with Epstein-Barr virus (EBV) positivity and non-diffuse large B cell lymphoma (non-DLBCL) histological type. MTX-LPDs are often diagnosed pathologically by lung biopsy. To the best of our knowledge, there have been no studies on the cytological diagnosis of MTX-LPD using sputum smears.</p> <p>A 70-year-old man, who was diagnosed with RA 13 years previously and who had been treated with MTX, presented shortness of breath and productive cough. MTX-LPD was suspected as the sputum cytology showed many atypical lymphoid cells with hyperchromatic enlarged nuclei, foamy cytoplasm and distinct nucleoli. Chest computed tomography revealed multiple nodular shadows with interstitial pneumonia in the bilateral lower lung field. A lung biopsy specimen contained atypical lymphoid cells that were immunohistochemically positive for CD20 and MUM-1, and weakly positive for bcl-6, but negative for CD3 and CD10. ISH-EBER showed no EBV-infectious lymphoid cells. He was finally diagnosed with MTX-LPD (Non-germinal center B-cell-like DLBCL histological type). Most of the nodules disappeared spontaneously following the withdrawal of MTX.</p> <p>A cytologically conclusive diagnosis of MTX-LPD may be reached using sputum smears and clinical information.</p>

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



Case report

The potential usefulness of sputum cytology in the conclusive diagnosis of methotrexate-associated lymphoproliferative disorders: A case report

Seiya Mizuguchi ¹, Kenichi Mizutani ², Manabu Yamashita ¹, Hiroshi Minato ³, Sohsuke Yamada ²

¹Department of Pathology, Kanazawa Medical University, Ishikawa, Japan; ²Department of Laboratory and Medicine, Kanazawa Medical University, Ishikawa, Japan; and ³Ishikawa Prefectural Central Hospital Department of Pathology, Ishikawa, Japan.

Short running title: The cytological diagnosis of MTX-LPD using sputum smears

Word count: 1189 Words (Abstract 220 Words); References: 6; and 2 Figures.

1
2
3
4
5
6
7
8 Corresponding author: Seiya Mizuguchi, Department of Pathology, Kanazawa Medical
9
10 University, 1-1 Uchinada, Ishikawa, 920-0293, Japan. Tel: 81-76-218-8264; Fax: 81-76-286-
11
12
13
14 1207; and E-mail: seiya-m@kanazawa-med.ac.jp
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For Peer Review

Abstract

Background: Methotrexate (MTX) has been used as an anchor drug for the treatment of rheumatoid arthritis (RA) and is considered to be a cause of MTX-associated lymphoproliferative disorder (MTX-LPD). Spontaneous regression can occur after withdrawal of MTX and may be associated with Epstein-Barr virus (EBV) positivity and non-diffuse large B cell lymphoma (non-DLBCL) histological type. MTX-LPDs are often diagnosed pathologically by lung biopsy. To the best of our knowledge, there have been no studies on the cytological diagnosis of MTX-LPD using sputum smears.

Case: A 70-year-old man, who was diagnosed with RA 13 years previously and who had been treated with MTX, presented shortness of breath and productive cough. MTX-LPD was suspected as the sputum cytology showed many atypical lymphoid cells with hyperchromatic enlarged nuclei, foamy cytoplasm and distinct nucleoli. Chest computed tomography revealed multiple nodular shadows with interstitial pneumonia in the bilateral lower lung field. A lung biopsy specimen contained atypical lymphoid cells that were immunohistochemically positive for CD20 and MUM-1, and weakly positive for bcl-6, but negative for CD3 and CD10. ISH-EBER showed no EBV-infectious lymphoid cells. He was finally diagnosed with

1
2
3
4 MTX-LPD (Non-germinal center B-cell-like DLBCL histological type). Most of the nodules
5
6
7 disappeared spontaneously following the withdrawal of MTX.
8
9

10
11 Discussion and Conclusion: A cytologically conclusive diagnosis of MTX-LPD may be
12
13
14 reached using sputum smears and clinical information.
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For Peer Review

Key words: MTX-associated lymphoproliferative disorders (MTX-LPD), sputum

For Peer Review

Background:

MTX has been used as an anchor drug for the treatment of RA and is considered to be a cause of MTX-LPD. The spontaneous regression of MTX-LPD can occur after the withdrawal of MTX and may be associated with EBV positivity and the non-DLBCL histological type [1]. Although the exact incidence is unknown, it is reported that 0.8% of RA patients develop LPD (RA-LPD) and approximately 80% of RA-LPD patients show a close association with MTX [2]. MTX-LPDs are often diagnosed pathologically using lung biopsy specimens. To the best of our knowledge, no studies have been reported on the cytological diagnosis of MTX-LPD using sputum smears.

Case:

A 70-year-old man, who had been diagnosed with RA 13 years previously and who have been treated with 6mg MTX per week and 1.5mg tacrolimus per day, presented shortness of breath and productive cough. Before the presentation, RA was controlled well without any symptoms such as arthritis, which could mean that activity of the disease was low. There were no other clinical symptoms such as fever up. A blood test showed high CRP

1
2
3
4 (1.32 mg/dl), LD (269 U/l) and sIL-2R (1860 U/ml) levels. EBV antibody tests confirmed
5
6
7 prior infection. Other results of blood test were as follows: RBC (3910000 / μ l), Hb (13.5
8
9
10 g/dl), WBC (6300 / μ l), AST (14 U/l), ALT (12 U/l), BUN (15 mg/dl), Cr (0.63 mg/dl). Chest
11
12
13 computed tomography revealed multiple nodular shadows with interstitial pneumonia in the
14
15
16 bilateral lower lung fields (Figure 1a, left). Since infectious pneumonia was suspected,
17
18
19 sputum cytology was performed. Macroscopically the sputum was colorless and showed no
20
21
22 atypical findings. Necrotic debris was observed in the background of the sputum cytology
23
24
25 (Figure 1b). The sputum cytology showed many atypical lymphoid cells with low cell
26
27
28 connectivity, a high nuclear to cytoplasmic (N/C) ratio, foamy cytoplasm, coarsely granular
29
30
31 chromatin, and distinct nucleoli (Figure 1 b,c). Cytomorphologically, reactive lymphoid
32
33
34 hyperplasia, lymphoproliferative disorder, adenocarcinoma and neuroendocrine tumor were
35
36
37 considered as the differential diagnoses. Bronchoscopy showed protuberating mucosa with
38
39
40 vascular proliferation and bleeding tendency. Lung biopsy revealed atypical mid- to large-
41
42
43 sized lymphoid cells with a high N/C ratio, cleaved nuclei and distinct nucleoli (Figure 1d).
44
45
46 Immunohistochemical staining of the lung biopsy specimen showed that the atypical
47
48
49 lymphoid cells were positive for CD20 (Figure 2a) and MUM-1 (Figure 2b), and weakly
50
51
52 positive for bcl-6, but negative for CD3 (Figure 2c) and CD10. ISH-EBER showed no EBV-
53
54

1
2
3
4 infectious lymphoid cells (Figure 2d). The patient was finally diagnosed with MTX-LPD
5
6
7 (Non-germinal center B-cell-like DLBCL histological type). Most of the nodules disappeared
8
9
10 spontaneously about 3 weeks after the withdrawal of MTX (Figure 1 a, right); thereafter, only
11
12
13 tacrolimus was used. Total follow-up period after MTX withdrawal was 15 months and there
14
15
16 is no progression of the disease.
17
18
19
20
21
22

23 **Discussion:**

24
25
26
27 In the World Health Organization (WHO) classification of lymphoid neoplasms,
28
29
30 MTX-LPDs are categorized as other iatrogenic immunodeficiency-associated
31
32
33 lymphoproliferative disorder (OIIA-LPD). Forty percent of MTX-LPD patients are EBV-
34
35
36 positive. Ichikawa et al. reported that approximately 40% of MTX-LPDs occurred at
37
38
39 extranodal sites and approximately 19% occurred in the lung. In approximately 83% of RA-
40
41
42 LPD patients, the condition was associated with MTX [3]. Approximately 55% of MTX-LPD
43
44
45 patients were diagnosed with the DLBCL histological type. Spontaneous regression of the
46
47
48 lesions occurred in approximately 60% of MTX-LPD patients after the withdrawal of MTX,
49
50
51 while progression after MTX withdrawal was observed in approximately 40% of MTX-LPD
52
53
54
55
56
57
58
59
60

1
2
3
4 patients. Spontaneous regression following MTX withdrawal has been associated with EBV
5
6
7 positivity and a non-DLBCL histological type of LPD, whereas age >70 years and the
8
9
10 DLBCL histological type are associated with shorter survival. In this case, it is interesting
11
12
13 that spontaneous regression occurred after the withdrawal of MTX, considering that the
14
15
16 patient was 70 years of age, was diagnosed with MTX-LPD (DLBCL histological type), and
17
18
19 was EBV-negative. No recurrence was reported.
20
21

22
23 Sensitivity of sputum cytology is highest for detecting squamous cell carcinoma and
24
25
26 malignant lymphoma of lung is usually reported on bronchoscopic specimen such as
27
28
29 bronchial brushings and washings [4]. Moreover, to the best of our knowledge, there are few
30
31
32 reports of malignant lymphoma diagnosed by sputum cytology. Although the exact rate is not
33
34
35 clear, frequency of malignant lymphoma diagnosed by sputum cytology is probably low.
36
37

38
39 The cytological, histological and immunohistochemical findings of MTX-LPD are
40
41 similar to those of malignant lymphoma in non-immunosuppressed hosts; thus, the diagnosis
42
43 of the entity is difficult with cytology alone, and clinical information is necessary. In this
44
45
46 case, with low cell cohesiveness, the atypical cells in the sputum smear were considered to be
47
48
49 lymphocytes. Although reactive lymphoid hyperplasia was a differential diagnosis, neoplastic
50
51
52
53
54

1
2
3
4 LPD was suspected based on the monotonous proliferation and high nuclear atypia of the
5
6
7 cells, and the necrotic background. Cell size and morphology are important criteria in
8
9
10 cytological diagnosis of malignant lymphoma. Considering size of atypical cells in sputum
11
12
13 specimen in this case, marginal zone lymphoma (MALT lymphoma), mantle cell lymphoma
14
15
16 and follicular lymphoma are included in differential diagnosis of histological type of MTX-
17
18
19 LPD. On the other hand, the most frequent type of MTX-LPD is DLBCL and that of MALT
20
21
22 lymphoma, mantle cell lymphoma and follicular lymphoma is very low, therefore, DLBCL is
23
24
25 also differential diagnosis. In our case, sputum cytology reported possibility of MTX-LPD
26
27
28 and suggested necessity of lung biopsy which led to diagnosis as DLBCL type. In addition to
29
30
31 our case, there have been some previous case reports of patients diagnosed with malignant
32
33
34 lymphoma. These patients were diagnosed with Hodgkin lymphoma [5] or Adult T-cell
35
36
37 leukemia/ lymphoma [6] based on sputum test and immunocytochemistry. Therefore, our
38
39
40 case indicates that the diagnosis of MTX-LPD based on sputum cytology is possible.
41
42
43
44
45
46

47 **Conclusion:**
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 We reported that cytological diagnosis of MTX-LPD was achieved using a sputum
5
6
7 smear with clinical information. The early detection of MTX-LPD is considered to be a
8
9
10 prognostic factor. Thus, simple and rapid sputum cytology is a useful tool for diagnosing
11
12
13 MTX-LPD occurring in the lung. This report shows the potential application of sputum
14
15
16 cytology in making a conclusive diagnosis of MTX-LPD without invasive lung biopsy.
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For Peer Review

1
2
3
4
5
6
7
8
9
10
11 **List of Abbreviations used**
12
13
14

15 MTX, methotrexate; RA, rheumatoid arthritis; LPD, lymphoproliferative disorders EBV,
16
17 Epstein-Barr virus; DLBCL, diffuse large B cell lymphoma; N/C, nuclear to cytoplasmic;
18
19 WHO, World Health Organization; OIIA-LPD, other iatrogenic immunodeficiency-
20
21 associated lymphoproliferative disorder.
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Acknowledgments

This paper is based upon a Presentation at the 56th Annual Autumn Meeting of the Japanese Society of Clinical Cytology, in 2017. We thank all of the members of our department.

Ethics approval and consent to participate

Not applicable.

Consent for Publication

Written informed consent for the publication of this case report and any accompanying images was obtained from the patient and his family on admission.

Availability of Data and Materials

The dataset supporting the findings and conclusions of this case report is included within the article.

1
2
3
4
5
6
7
8 **Funding**
9

10
11 Not applicable.
12
13

14
15
16
17
18
19 **Conflicts of Interests**
20

21
22 The authors declare that there is no conflict of interest in association with the present study.
23
24
25
26
27
28
29

30 **Author contributions**
31

32
33 SM, KM and SY participated in the conception of the idea and writing of the manuscript.
34
35

36 SM, KM, MY, HM and SY performed the clinical investigation and
37

38
39 pathological/immunohistochemical examination. All authors have read and approved the final
40
41
42 manuscript.
43
44
45
46
47
48
49
50
51
52
53
54

References


1. Steven HS, Elias C, Nancy LH, Elaine SJ, Stefano AP, Harald S, Jürgen T, Daniel AA, Robert PH, Michelle MLB, Attilio O, Reiner S. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Revised 4th edn. Lyon, France: IARC press 2017
2. Shimizu Y, Nakajima A, Inoue E, Shidara K, Sugimoto N, Seto Y, Tanaka E, Momohara S, Taniguchi A, Yamanaka H. Characteristics and risk factors of lymphoproliferative disorders among patients with rheumatoid arthritis concurrently treated with methotrexate: a nested case-control study of the IORRA cohort. *Clin Rheumatol* 2017, 36:1237-1245
3. Ichikawa A, Arakawa F, Kiyasu J, Sato K, Miyoshi H, Niino D, Kimura Y, Takeuchi M, Yoshida M, Ishibashi Y, Nakashima S, Sugita Y, Miura O, Ohshima K. Methotrexate/iatrogenic lymphoproliferative disorders in rheumatoid arthritis: histology, Epstein-Barr virus, and clonality are important predictors of disease progression and regression. *European Journal of Haematology* 2013, 91: 20-28
4. Paolo G, Vijaya B, Shahla. *Differential Diagnosis in Cytopathology*. 1st edn. Cambridge, United Kingdom: Cambridge University Press 2010

1
2
3
4 5. AbdullGaffar B, Khalid M, Samuel R. Unsuspected Hodgkin lymphoma first diagnosed by
5
6
7 sputum cytology. *Diagn Cytopathol* 2011, 39(8): 631-633
8

9
10
11 6.Jia Q, Jinli L, Constantine AA. Cytological Diagnosis of Adult T-Cell
12
13
14 Leukemia/Lymphoma in Sputum. *Diagn Cytopathol* 2016, 44(5): 416-418
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For Peer Review

Figure 1.



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 2.




Figure Legends

Figure 1. Computed tomography, the cytological findings of the sputum, and the histological findings of the lung biopsy specimen.

- (a) Computed tomography on admission showed multiple nodular shadows in the bilateral lower lung field (left). Most of the nodular shadows disappeared spontaneously after the withdrawal of MTX (right).
- (b) A sputum smear on admission showed many atypical small cells with low cell cohesion (left). Necrotic debris was observed in the background of the sputum cytology (right) (Papanicolau staining; original magnification, $\times 400$).
- (c) A high-power view of the sputum revealed that the atypical cells had a high N/C ratio, foamy cytoplasm, increased chromatin and distinct nucleoli. (Papanicolau staining; original magnification, $\times 1,000$).
- (d) Lung biopsy after sputum cytology revealed atypical lymphoid cells with high N/C ratio, cleaved nuclei and distinct nucleoli (HE staining) (original magnification: $\times 400$).

1
2
3
4 Figure 2. Immunohistochemical staining of a lung biopsy specimen showed that the atypical
5
6
7 lymphoid cells were positive for CD20 (a) and MUM-1 (b), but negative for CD3 (c). ISH-
8
9
10 EBER (d) was negative (original magnification: $\times 200$).
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For Peer Review

1
2
3 **(1) Ethics approval**
4
5

6 Our institution does not require ethical approval for reporting individual cases or case series.
7

8 **(2) Informed consent**
9

10 Written informed consent was obtained from the patient for their anonymized information to be published in
11 this article.
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For Peer Review